AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26488269 — intervention group
Group type: EXPERIMENTAL
Intervention: MeFirst intervention
Number of subjects: 661
Study 26488269 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 661
Study 22526891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraseptal anesthesia (ISA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Number of subjects: 180
Study 22526891 — intervention group
Group type: COMPARATOR
Intervention: Periodontal ligament anesthesia (PLA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Number of subjects: 180
Study 21546066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (specifics not provided)
Number of subjects: 0
Study 21546066 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 0
Study 21546066 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 PFS status at 4 months (PFS4) in combination treatment
Number of subjects: 0
Study 21546066 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 response in combination treatment
Number of subjects: 0
Study 21546066 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 PFS4 in combination treatment
Number of subjects: 0
Study 21546066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CA-125 decrease
Number of subjects: 0
Study 19178441 — intervention group
Group type: EXPERIMENTAL
Intervention: STIMBELT (electrical stimulation system with lumbar belt and electrodes)
Number of subjects: 0
Study 19178441 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 17990464 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD) and Glauber's salt (GS)
Number of subjects: 65
Study 17990464 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy without QYD and GS)
Number of subjects: 65
Study 16392707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (70% energy from fat)
Number of subjects: 14
Study 16392707 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (20% energy from fat)
Number of subjects: 14
Study 12397705 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Number of subjects: 4000
Study 12397705 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 4000
Study 9803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril (0.5 mg)
Number of subjects: 0
Study 9803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril (2.5 mg)
Number of subjects: 0
Study 9803988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7897075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy using essential oil of lavender
Number of subjects: 122
Study 7897075 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 122
Study 7897075 — intervention group
Group type: EXPERIMENTAL
Intervention: Period of rest
Number of subjects: 122
Study 2930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing plans with full catastrophic coverage
Number of subjects: 0
Study 2930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing plans
Number of subjects: 0
Study 2930328 — intervention group
Group type: COMPARATOR
Intervention: Free-care plan
Number of subjects: 0
Study 389121 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg)
Number of subjects: 128
Study 389121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologically inactive dose (1 mg)
Number of subjects: 128
Study 389121 — intervention group
Group type: COMPARATOR
Intervention: No disulfiram
Number of subjects: 128
Study 30983387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation plus nine months after‐care with face‐to‐face group lifestyle counseling
Number of subjects: 740
Study 30983387 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 740
Study 30983387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation plus nine months after‐care with individual lifestyle telephone counseling
Number of subjects: 740
Study 30015674 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Girth (AG) measurement
Number of subjects: 0
Study 30015674 — intervention group
Group type: COMPARATOR
Intervention: Gastric Residual Volumes (GRV) assessment
Number of subjects: 0
Study 27358255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of levobupivacaine
Number of subjects: 438
Study 27358255 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 438
Study 25087311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavac administered second (Group A)
Number of subjects: 184
Study 25087311 — intervention group
Group type: COMPARATOR
Intervention: Pentavac administered first (Group B)
Number of subjects: 184
Study 22058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin therapy
Number of subjects: 0
Study 22058086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19039304 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]HYNIC annexin V (treated group)
Number of subjects: 11
Study 19039304 — intervention group
Group type: COMPARATOR
Intervention: [(99m)Tc]HYNIC annexin V (control group)
Number of subjects: 11
Study 17925179 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of posterior cord
Number of subjects: 70
Study 17925179 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of lateral cord
Number of subjects: 70
Study 15010066 — intervention group
Group type: EXPERIMENTAL
Intervention: Glufosfamide 5000 mg/m² by 1-hour intravenous infusion every 3 weeks
Number of subjects: 39
Study 15010066 — intervention group
Group type: COMPARATOR
Intervention: Hydration (randomised group)
Number of subjects: 39
Study 15010066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 39
Study 11758323 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration of 0.5% bupivacaine into the surgical wound before surgery combined with general anesthesia (Group L)
Number of subjects: 45
Study 11758323 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia combined with general anesthesia (Group E)
Number of subjects: 45
Study 11758323 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Group C)
Number of subjects: 45
Study 9683329 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Meal (HP)
Number of subjects: 10
Study 9683329 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Meal (HC)
Number of subjects: 10
Study 9683329 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat Meal (HF)
Number of subjects: 10
Study 7885940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast chronotropic response pattern
Number of subjects: 13
Study 7885940 — intervention group
Group type: COMPARATOR
Intervention: Linear chronotropic response pattern
Number of subjects: 13
Study 7885940 — intervention group
Group type: COMPARATOR
Intervention: Slow chronotropic response pattern
Number of subjects: 13
Study 3381964 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive diet (advice to restrict intake of red meat and peroxidase-containing vegetables)
Number of subjects: 786
Study 3381964 — intervention group
Group type: COMPARATOR
Intervention: No diet (control group)
Number of subjects: 786
Study 30908574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 47
Study 30908574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30908574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol responders
Number of subjects: 47
Study 30908574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol nonresponders
Number of subjects: 47
Study 29550881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (0.5 mg/2 weeks followed by 1.0 mg/6 weeks)
Number of subjects: 47
Study 29550881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28873768 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web‐based mobile reminder calendar
Number of subjects: 0
Study 28873768 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25785695 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (taught on day 1 and tested on days 10, 20, and 30)
Number of subjects: 0
Study 25785695 — intervention group
Group type: COMPARATOR
Intervention: Control group (taught on day 1 and tested for proficiency on day 30)
Number of subjects: 0
Study 25785695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 23302446 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/day for 4 weeks with antipsychotic treatment
Number of subjects: 32
Study 23302446 — intervention group
Group type: COMPARATOR
Intervention: Placebo booster with antipsychotics
Number of subjects: 32
Study 21971661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group GP)
Number of subjects: 20
Study 21971661 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group GS)
Number of subjects: 20
Study 18979881 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Nuss procedure
Number of subjects: 21
Study 18979881 — intervention group
Group type: COMPARATOR
Intervention: Recurrent Ravitch procedure
Number of subjects: 21
Study 18979881 — intervention group
Group type: COMPARATOR
Intervention: Primary Nuss procedure
Number of subjects: 21
Study 16531920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐sestamibi
Number of subjects: 29
Study 14652528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with music
Number of subjects: 33
Study 14652528 — intervention group
Group type: COMPARATOR
Intervention: Exercise without music (control)
Number of subjects: 33
Study 15806975 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) plus stanozol and cyclosporin A
Number of subjects: 60
Study 15806975 — intervention group
Group type: COMPARATOR
Intervention: Stanozol and cyclosporin A alone (Control)
Number of subjects: 60
Study 10613172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound
Number of subjects: 30
Study 10613172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7574195 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis (250 mg/d) for cohort 1, administered as 500 mg on day 14 before challenge, followed by 250 mg/d from day 13 before challenge through day 7 after challenge.
Number of subjects: 24
Study 7574195 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis (250 mg/d) for cohort 2, continued for 28 days after the challenge.
Number of subjects: 24
Study 7574195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) for both cohorts.
Number of subjects: 24
Study 2037705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (0.1 mg/kg)
Number of subjects: 0
Study 2037705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (0.1 mg/kg) with propranolol pretreatment
Number of subjects: 0
Study 7308332 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg bromhexine (4 mg in two patients)
Number of subjects: 12
Study 7308332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31124581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m²/day)
Number of subjects: 599
Study 31124581 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (60 mg/m²/day)
Number of subjects: 599
Study 29032379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bicarbonate
Number of subjects: 40
Study 29032379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25592094 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 41
Study 25592094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training (CT)
Number of subjects: 41
Study 25592094 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 41
Study 25592094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IT and CT
Number of subjects: 41
Study 25592094 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT) vs Continuous Training (CT)
Number of subjects: 41
Study 25592094 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 41
Study 24673168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP) plus early learning (integrated intervention)
Number of subjects: 0
Study 24673168 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP alone
Number of subjects: 0
Study 24673168 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus early learning
Number of subjects: 0
Study 24673168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21102344 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (placebo-controlled)
Number of subjects: 3266
Study 19725342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex administered at a dosage of 2 mg x kg(‐1)
Number of subjects: 20
Study 19725342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 20
Study 19725342 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 20
Study 19725342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 20
Study 18027087 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (restricted to 30% of patients with advanced/aggressive disease)
Number of subjects: 350
Study 18027087 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy (largely eliminated)
Number of subjects: 350
Study 18027087 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative treatment regimens (randomized trials)
Number of subjects: 350
Study 15130189 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced and complementary processing of text/adjunct information
Number of subjects: 80
Study 15130189 — intervention group
Group type: COMPARATOR
Intervention: Non-complementary processing
Number of subjects: 80
Study 11159473 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque suturing technique
Number of subjects: 53
Study 11159473 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitorque suturing technique
Number of subjects: 53
Study 11159473 — intervention group
Group type: EXPERIMENTAL
Intervention: No torque suturing technique
Number of subjects: 53
Study 9771153 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a breast care nurse (Group II, n = 366)
Number of subjects: 717
Study 9771153 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (Group I, n = 351)
Number of subjects: 717
Study 8091361 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 25776 500 mg
Number of subjects: 8
Study 8091361 — intervention group
Group type: COMPARATOR
Intervention: triazolam 0.25 mg
Number of subjects: 8
Study 31900963 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of disease
Number of subjects: 1607
Study 31900963 — intervention group
Group type: COMPARATOR
Intervention: Stable disease
Number of subjects: 1607
Study 31900963 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 1607
Study 31900963 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with time to progression
Number of subjects: 1607
Study 31900963 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery progression
Number of subjects: 1607
Study 30460402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy plus platelet-rich plasma (PRP) therapy (TPRP group)
Number of subjects: 80
Study 30460402 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy alone (TA group)
Number of subjects: 80
Study 28870263 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum
Number of subjects: 2300
Study 28870263 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo regimen
Number of subjects: 2300
Study 26254953 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor hand-bike exercise program (60-minute sessions, 3 times per week for 6 weeks)
Number of subjects: 15
Study 23335291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation intervention
Number of subjects: 429
Study 23335291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study 21943365 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) colonoscopy
Number of subjects: 482
Study 21943365 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 482
Study 18306007 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit anesthesia (CCA)
Number of subjects: 40
Study 18306007 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat moisture exchangers (HMEs) in CCA
Number of subjects: 40
Study 18306007 — intervention group
Group type: COMPARATOR
Intervention: Semi-closed anesthesia (SCA)
Number of subjects: 40
Study 16569797 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium delayed-release (DR)
Number of subjects: 28
Study 16569797 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (ER)
Number of subjects: 28
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of oocyte donation
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposition to oocyte donation
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubt about oocyte donation
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors increasing willingness to donate
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings about helping childless couples
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with offspring
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of genetic link
Number of subjects: 1000
Study 14507845 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental status of potential donors
Number of subjects: 1000
Study 11246599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone
Number of subjects: 0
Study 11246599 — intervention group
Group type: COMPARATOR
Intervention: Marvelon (ethinylestradiol/desogestrel)
Number of subjects: 0
Study 8721265 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg/d)
Number of subjects: 64
Study 8721265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 1551152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal ibuprofen (40 mg.kg‐1.day‐1 in divided doses)
Number of subjects: 128
Study 1551152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 3565028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid
Number of subjects: 237
Study 3565028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid combined with 2 Lf diphtheria toxoid
Number of subjects: 237
Study 3565028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid combined with 5 Lf diphtheria toxoid
Number of subjects: 237
Study 3565028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 237
Study 31233117 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) in primary care
Number of subjects: 140
Study 31233117 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) at local hospital
Number of subjects: 140
Study 29688793 — intervention group
Group type: COMPARATOR
Intervention: High-dose BNR (BNR-H, 1010 CFU/day)
Number of subjects: 90
Study 29688793 — intervention group
Group type: COMPARATOR
Intervention: Low-dose BNR (BNR-L, 109 CFU/day)
Number of subjects: 90
Study 29688793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29688793 — intervention group
Group type: COMPARATOR
Intervention: Biochemical parameters
Number of subjects: 90
Study 26456200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IA therapy)
Number of subjects: 517
Study 24866496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose resveratrol (300mg/day)
Number of subjects: 32
Study 24866496 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose resveratrol (1000mg/day)
Number of subjects: 32
Study 24866496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22702148 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-analogue scale (VAS) for anxiety assessment
Number of subjects: 156
Study 20461567 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based SCC tool
Number of subjects: 100
Study 20461567 — intervention group
Group type: COMPARATOR
Intervention: Paper-based reminder tool
Number of subjects: 100
Study 18478253 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + IMT (Inspiratory Muscle Training at 80% SMIP, 3 days/week)
Number of subjects: 30
Study 18478253 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + SHAM-IMT (Sham Inspiratory Muscle Training)
Number of subjects: 30
Study 18478253 — intervention group
Group type: COMPARATOR
Intervention: ST (Swim Training only)
Number of subjects: 30
Study 15813664 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol HFA (Oxis) 2 x 4.5microg
Number of subjects: 30
Study 15813664 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol HFA (Ventoline) 2 x 100microg
Number of subjects: 30
Study 15813664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12500859 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated practice in color discrimination tasks
Number of subjects: 0
Study 12500859 — intervention group
Group type: EXPERIMENTAL
Intervention: Category learning
Number of subjects: 0
Study 12500859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hue- and lightness-based category learning
Number of subjects: 0
Study 12500859 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10711985 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne and Becker dystrophies
Number of subjects: 0